$59.99
Research Studies:
Out of stock
FREE Shipping on
orders over $200
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.
Mechano Growth Factor (MGF) 5mg is a research-use-only laboratory material supplied for controlled research workflows, compound characterization, and analytical documentation review. It is manufactured under rigorous quality standards to support consistency, traceability, and batch-specific verification for qualified laboratory settings.
Mechano Growth Factor (MGF) 5mg is intended strictly for laboratory research use only. This product is not intended for human or animal consumption, therapeutic use, diagnostic use, clinical use, veterinary use, or as a food, drug, cosmetic, dietary supplement, or household product.
| CAS No. | 62031-54-3 |
|---|---|
| Sequence | YQPPSTNKNTKSQRRKGSTFEEHK-NH2 |
| Molecular Formula | C121H200N42O39 |
| Molecular Weight | 2867.2 g/mol |
| Applications | Muscle regeneration studies, tissue repair research, anti-aging investigations |
| Purity | ≥99% |
| Synthesis | Solid-phase synthesis |
| Solubility | Soluble in water or 1% acetic acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Appearance | White lyophilized powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
| Safety Information | Refer to provided MSDS |
Consider these supplementary peptides for a comprehensive research approach.
Researchers evaluating where to buy MGF for research should begin with documentation, not outcome language. MGF, also called mechano growth factor in published literature, is discussed as an IGF-1-related peptide research entity and should be framed only for laboratory research-use-only context. This Pure Lab Peptides guide explains how research buyers can evaluate MGF peptide identity, literature context, COA details, analytical testing, lot traceability, and RUO positioning without converting research findings into product claims.
Researchers looking to buy MGF for research should first review the product listing, RUO label, batch-specific COA, peptide purity data, identity testing, lot number, and storage documentation. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. The safest commercial research path is documentation-led procurement, not consumer-style product interpretation.
The phrase buy MGF for research turns a commercial query into a technical procurement task. Instead of asking what a product is “for” outside the lab, a research buyer should ask whether the MGF research material is clearly labeled, traceable, and supported by batch-specific documentation.
This approach also keeps the original buy mgf intent inside an RUO frame. Search phrases that drift toward sale online language should be redirected back to COA review, analytical testing, and research documentation.
The first documents to review are the product label, batch-specific certificate of analysis, lot identifier, purity data, identity data, and storage notes. For peptide materials, analytical sources commonly separate identity-related testing from purity-related testing, so both should be reviewed before a lab records the material in a procurement file [19], [20].
RUO labeling helps separate research materials from diagnostic, clinical, or consumer-facing positioning. FDA guidance on RUO and IUO labeling is IVD-specific, but it illustrates a broader documentation principle: research labeling should align with research intent and should not be contradicted by product messaging [18].
MGF research materials belong in a laboratory documentation context. A product page should help qualified research teams understand what documentation exists, what identity terms appear in the literature, and what analytical records can support procurement review.
Research-use-only positioning means the page is not a personal-use guide, a wellness page, a fitness page, or a clinical discussion. It should explain the MGF peptide as a research compound and keep the product-page focus on identity, COA, purity, lot traceability, and technical documentation.
Pure Lab Peptides product-page copy should keep MGF peptide content tied to laboratory research, not outcome claims. That means compound naming, published literature context, analytical testing, supplier documentation, and handling records should carry the page.
MGF is commonly discussed as mechano growth factor, a term connected to IGF-1 splice-variant literature. NCBI lists IGF1 as a human protein-coding gene and includes MGF among its synonyms, while Protein Ontology also connects IGF-I and mechano growth factor terminology in its IGF1 entry [1], [3].
MGF research sits in a growth factor peptide research lane because the terminology is tied to insulin-like growth factor 1, IGF-I, and splice-variant discussions. UniProt identifies human IGF1 under accession P05019, while NCBI records IGF1 as a protein-coding gene with multiple related protein records [2], [1].
Mechano growth factor is discussed in the literature as an IGF-1-related splice-variant topic rather than as a standalone consumer product concept. A major minireview by Matheny and colleagues emphasized the need to distinguish synthetic MGF peptide research from known products of the Igf1 gene [4].
MGF nomenclature can include mechano growth factor, IGF-1Ec, IGF-I Ec, E-domain peptide, and growth factor E peptide language. Reviews of IGF1 splicing describe how alternative transcripts and post-translational processing create terminology complexity, which is why product pages should avoid oversimplified identity claims [5], [6].
A careful MGF peptide review starts by matching the product name against literature language and analytical documentation. The goal is not to use every synonym on the product page, but to prevent mismatch between listing language, COA language, and research literature.
Growth factor E peptide language usually refers to the E-domain portion discussed in IGF-1Ec / MGF literature. Vassilakos and colleagues reviewed synthetic IGF-1Ec E-domain peptide literature and noted that synthetic peptides require careful distinction from full-length pro-IGF-1Ec discussions [14].
Isoform language helps researchers connect MGF references with IGF-1 splice-variant literature. Reviews of IGF1 gene transcription and splicing describe how promoter usage, RNA splicing, and transcript variation create different IGF1 isoform contexts [5], [6].
The scientific background for MGF is mainly built from IGF-1, IGF-I, splice variant, satellite cell, and E-domain peptide literature. Goldspink and colleagues are frequently cited in early work on IGF-I gene splicing and mechano growth factor terminology [7], [9].
Alternative splicing is central to how MGF is classified in research literature. IGF1 reviews describe multiple mRNA and protein isoform contexts, and those distinctions help explain why MGF, IGF-1Ec, IGF-I Ec, and E-domain terminology need precise handling [5], [6].
IGF-I gene literature helps researchers interpret whether a paper is discussing mature IGF-I, an IGF-I Ec peptide, a full-length precursor form, or a synthetic peptide model. Hill and Goldspink reported that expression and splicing of the insulin-like growth factor gene in rodent muscle was associated with satellite cell activation in a local model context [7].
Published models can establish research observations inside defined assay systems, but they cannot be converted into broad product claims. That caution matters in MGF research because some studies reported cell-model activity while later work raised replication and interpretation questions [10], [16].
MGF pathway research is best framed through model type, peptide form, endpoint, and limitation. The literature includes in vitro models, preclinical model systems, and reviews that compare mature IGF-1 with E-domain peptide research [4], [10], [15].
Cell signaling context should be described as literature context only. Brisson and Barton reported that IGF-I E-peptide activity in their model was dependent on IGF-I receptor context, which shows why mechanistic interpretation should stay model-specific [15].
Satellite cell models add a focused cellular lens to the MGF literature. Kandalla and colleagues examined MGF-E peptide in primary human muscle cell cultures and reported age-related differences in proliferation and differentiation readouts within that research model [11].
Proliferation and differentiation findings need limits because they depend on cell type, peptide form, assay conditions, and study design. Yang and Goldspink reported different roles for IGF-I Ec peptide and mature IGF-I in a myoblast model, while Fornaro and colleagues later reported no apparent activity in their tested myoblast and primary muscle stem cell systems [10], [16].
Cell-model context explains what kind of system produced a finding. For MGF research, the difference between a muscle cell model, satellite cell model, mesenchymal stem cell model, and other cell culture setting can change how the literature should be interpreted.
In vitro research provides controlled experimental conditions for studying cell signaling, proliferation, differentiation, and related readouts. It does not automatically translate into procurement claims for an RUO peptide product page.
Mesenchymal stem cell research appears in MGF-related literature as a model category for studying migration and proliferation signals. Collins and colleagues reported that different regions of the MGF prohormone stimulated migration and proliferation of human mesenchymal stem cells in experimental systems, and Cui and colleagues studied MGF E peptide in rat bone marrow-derived mesenchymal stem cells [12], [13].
A strong evidence interpretation framework separates model type, peptide form, endpoint, and RUO implication. This helps product-page readers understand the research landscape without turning published findings into product-positioning claims.
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| IGF1 identity | IGF1 gene, protein records, and MGF synonym mapping [1], [2], [3] | Official database | Supports terminology review, not product claims |
| Splice-variant context | IGF1 transcription, RNA splicing, and isoform complexity [5], [6] | Review literature | Helps match literature language to documentation |
| Muscle cell models | IGF-I Ec peptide and mature IGF-I comparisons [10], [11] | In vitro literature | Model findings remain study-specific |
| Mesenchymal stem cell models | Migration and proliferation readouts in defined systems [12], [13] | In vitro / preclinical model literature | Useful for model selection, not outcome positioning |
| Replication and limits | Contrasting findings in synthetic MGF peptide studies [15], [16] | Mechanistic literature | Supports cautious evidence interpretation |
Sources for table entries include official database records, IGF1 splice-variant reviews, and model-specific MGF peptide studies.
Study design shapes relevance by defining the peptide form, model system, exposure conditions, endpoint, and analytical methods. This is especially important for MGF research because synthetic peptide studies and IGF1 splice-variant studies are not interchangeable [4], [14], [16].
Preclinical findings need careful context because they are bound to the model, assay, and endpoint used by the research team. A safer RUO reading is to treat those findings as literature context that informs research questions, not as product-page promises.
Source quality signals include peer-reviewed publication status, official database support, clear peptide identity, transparent methods, and whether the paper distinguishes synthetic peptide work from IGF1 gene-product biology. Synthetic peptide quality studies also show why identity and purity review can matter for research reproducibility [29].
Research literature can describe model-specific observations, but an RUO product page should not convert those observations into claims about a research material. Boundary-sensitive phrases related to product effects or product performance can become claims if they are separated from study context.
Study findings belong in literature discussion, not in the product listing’s intended-purpose language. For MGF research, a finding from a satellite cell or mesenchymal stem cell model should remain tied to that model, source, peptide form, and limitation.
Claim boundaries mean the page can explain what the literature examines, what documentation should be reviewed, and what analytical testing can confirm. It should not suggest that published literature changes the RUO status of any Pure Lab Peptides research material.
COA documentation matters because research procurement needs batch-level evidence. A certificate of analysis should help connect the label, lot number, compound name, purity result, identity result, method summary, and test date.
A COA should identify the compound name, lot number, tested batch, analytical method, purity result, identity confirmation, test date, and laboratory source. ICH Q2(R2) discusses analytical procedures for identity, purity, impurities, and quantitative or qualitative measurements, while ICH Q6B describes specifications for proteins and polypeptides as part of a quality framework [19], [20].
Batch-specific results help a lab confirm that the documentation matches the actual research material under review. Reference-standard literature for synthetic peptides discusses vialing, lyophilization, analytical testing, and stability studies as documentation-relevant quality elements [21].
Purity, identity, and mass data align when chromatographic purity results, mass spectrometry data, and batch identifiers all point to the same material. Mass spectrometry is well suited to synthetic peptide identity and purity assessment, while LC-MS can support peptide characterization when method limitations are understood [23], [24].
Analytical testing should be read as a workflow, not a single number. For peptide procurement, HPLC, LC-MS, mass spectrometry, chromatogram review, mass-to-charge interpretation, and batch matching all serve different documentation roles.
Numbered lab-test verification workflow:
HPLC supports peptide purity review by separating peptide-related components under defined chromatographic conditions. Mant and colleagues describe HPLC modes used for peptide analysis and purification, including reversed-phase, ion-exchange, and size-exclusion approaches [22].
LC-MS supports identity verification by pairing chromatographic separation with mass-based detection. Reviews of synthetic peptide characterization describe LC-MS as a key method for identifying and characterizing peptide materials and related impurities [24], [25].
Chromatogram and mass-spectrometry details matter because a purity percentage alone does not prove complete identity. Peptide characterization literature describes how mass spectrometry can support identity review, while HPLC supplies chromatographic purity information under defined method conditions [22], [23], [24].
Lot traceability connects a research material to its batch-specific records. For MGF peptide research materials, traceability should include the label, COA, lot identifier, test date, and any available analytical files.
Lot numbers add a control point for matching the research material to the correct COA and documentation set. Without a lot-level link, a purity result or identity result can become too generic for procurement review.
Batch records support consistency by confirming that the product listing, label, and COA describe the same MGF research material. This is especially important when literature uses overlapping terms such as MGF, mechano growth factor, IGF-1Ec, and growth factor E peptide.
Supplier documentation should show whether the research material is described consistently from listing to label to COA. Handling of peptides should be recorded in a laboratory documentation system, especially when a product is supplied in a lyophilized format or has specific storage notes.
Lab teams should compare compound name, lot number, purity result, identity result, test date, storage information, and label language. OSHA’s laboratory safety materials and NIH chemical-safety guidance both emphasize written laboratory safety systems, chemical information review, and accessible safety documentation for laboratory work [26], [27].
Storage information belongs in documentation review because it helps the lab maintain a consistent record from receipt through research handling. Reference-standard literature also treats lyophilization, stability studies, and analytical testing as connected documentation considerations for synthetic peptide quality [21].
Before teams buy MGF for research, procurement should be handled as a documentation checklist. The checklist below keeps the product-page review focused on RUO documentation rather than claim language.
Review MGF research materials by separating product documentation from literature interpretation. Peptide synthesis literature explains how synthetic peptides are created as defined amino-acid sequences, but a product-page review should still depend on COA, identity, purity, and lot records rather than assumptions from naming alone [28].
The strongest documentation signals are a clear RUO label, batch-specific COA, matching lot number, purity method, identity method, mass data, storage notes, and consistent supplier documentation. Common misunderstandings to avoid include treating literature findings as listing claims, treating a purity percentage as complete identity proof, treating a generic COA as batch-specific evidence, and treating catalog specifications as research-positioning signals.
Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.
Review the product-page documentation, COA details, analytical testing, lot traceability, and RUO labeling before evaluating MGF for laboratory research procurement.
Research use only means MGF is intended solely for qualified laboratory research contexts. It should be evaluated through product documentation, RUO labeling, COA review, peptide identity, analytical testing, and lot traceability. This positioning keeps the page focused on research documentation rather than consumer-facing interpretation or product-purpose claims.
MGF is not intended for human or animal consumption. In a Pure Lab Peptides product-page context, MGF is discussed only as a laboratory research material. Researchers should review the COA, label, batch documentation, and supplier records to confirm that the material is framed for research-use-only evaluation.
Researchers should consider documentation quality before they buy MGF for research. Key review points include RUO labeling, batch-specific COA availability, lot traceability, peptide purity, peptide identity, and consistency between the product listing and supporting records. Commercial research intent should stay focused on documentation rather than product-claim language.
Published literature about MGF should be interpreted as research context, not product-purpose guidance. Papers may discuss mechano-growth factor, IGF-I, splice variant of IGF-1 terminology, skeletal muscle models, or muscle tissue research settings. Those findings should remain tied to the model, peptide form, and study limits described in the literature.
An MGF COA matters because it provides batch-specific documentation for research procurement review. A useful COA helps connect the compound name, lot number, purity data, identity testing, method summary, and test date. It should be reviewed alongside the label and supplier documentation rather than treated as a standalone assurance.
Language boundaries matter because some phrases can drift into product-claim territory if they are not clearly framed. Terms such as pegylated mechano growth factor, potential of MGF, and full-length MGF should be handled as literature or terminology context only. RUO pages should redirect attention to compound identity, COA review, analytical testing, lot traceability, and documentation.
The following authors are recognized for published research that helped shape the scientific context discussed in this article.
Author profile: ResearchGate
Geoffrey Goldspink’s published work is closely tied to the terminology and model-based literature surrounding MGF, IGF-I gene splicing, and satellite-cell research models. His publications helped shape the broader scientific context for discussing MGF as a mechano growth factor topic within IGF-I splice-variant literature. That work is relevant to this article’s research-use-only framework because it supports careful interpretation of compound identity, peptide nomenclature, and model-specific findings without converting research observations into product-positioning claims.
Selected publications:
Author profile: University of Portsmouth Research Portal
Dariusz C. Górecki’s publications are relevant to the MGF research lane because they address IGF-1 isoform terminology, alternative splicing, and model-specific interpretation across the published literature. His work provides useful context for understanding why MGF references should be read through peptide identity, isoform language, and literature boundaries. This is especially relevant for a research-use-only product page where scientific background, pathway context, and documentation review must remain separate from product-purpose claims.
Selected publications:
This research disclaimer clarifies how this page handles published literature and search language around MGF. In Growth Factor Peptide Research content, phrases such as buy peg-MGF peptide, MGF exposure, action of MGF, neuroprotective, cardiac function, ischemia, tissue repair, regeneration, and muscle growth can drift into consumer-facing, wellness, clinical-use, therapeutic, or product-claim language when framed incorrectly.
Here, those phrases are treated only as research-language examples or literature-boundary signals, not as product positioning, outcomes, instructions, or recommendations. The focus remains on MGF identity, COA review, analytical testing, peptide purity, lot traceability, RUO labeling, product documentation, and published literature boundaries, including careful separation of human study language, consumer outcomes, therapeutic language, and administration-focused language from research-use-only product-page content.
Our team is ready to assist you with any inquiries regarding our catalogue of peptides and their applications.
Discount Applied Successfully!
Your savings have been added to the cart.
There are no reviews yet.